Abstract
H
worldwide public health problem. Two billion people worldwide have serologic evidence of chronically infected and at risk for HBV-related liver disease.
in the general population. 5, 6 Hepatitis B vaccination is the most effective method to prevent HBV transmission and its consequences.
Three doses of HB vaccine induces protective antibody to HB surface antigen (antiand young adults. However, anti-HBs decline over time and the vaccine-related protective duration is a completed primary HB vaccine series showed that titers or undetectable anti-HBs.
proportion of healthy individuals who had received complete HB vaccinations did not achieve protective (> Non-immune adolescents are potentially at risk of acquiring HBV infection due to horizontal transmission, in particular those who engage in multiple partners, tattooing, or injection-drug use. Studies on immunity against HBV in adolescence have been reported from a few countries. However, hepatitis B, is limited. Furthermore, data on primary HB vaccinations have not been well documented, as it is often based on the parents' memory recall. We carried out a preliminary study aimed to determine had received the primary HB vaccine series, based on their vaccination history, and their response to a booster dose of HB vaccine given to individuals who had non-protective anti-HBs levels. 
Methods

Results
received the complete primary HB vaccine series during infancy were included in our study. Subjects were students from three public senior high schools below the 5 th th th percentile th booster doses of HB vaccine. None had evidence of chronic infection, immunodeficiency disease, or were taking any immunosuppressive medicine at the time of study recruitment.
Subjects' serological status against HBV prior to the study was unknown. Based on blood test for pre-booster anti-HBs titers, subjects were classified > Table 1 showed protective anti-HBs with a median of undetectable anti-HBs.
One subject preferred to receive the HB vaccine from her own doctor and could not be analyzed further. No serious adverse events to the booster dose were significant seroconversion among vaccinated subjects
Figure 1 achieved seroconversion to protective anti-HBs titers with a median of , anti-HBs titers, hence, they were categorized as nonresponders. Subjects were classified into one of four categories of post-booster anti-HBs titers, as they were for pre-booster anti-HBs titers (Table 1 Subjects were divided into groups according to age, gender, and nutritional status categories to determine anti-HBs responses after the HB vaccine booster doses among groups. There were no significant differences in post-booster anti-HBs titers among the different categories of age, gender, or nutritional titers for all subjects subdivided by age, gender, and nutritional status categories are shown in Table 2 .
protective anti-HBs titers. Therefore, a total of had protective anti-HBs, including both pre-booster and post-booster responders. However, after administration of the HB vaccine rate protective anti-HBs titers. Overall, the prevalence The possibility of waning immunity or eventual loss of the vaccine protectiveness should be are not detected a few years after the third dose of the vaccine, those with non-protective anti-HBs titers should be given a single HB vaccine booster dose, a booster doses. This result indicated that nonprotective anti-HBs titers in most subjects were due to waning immunity.
A rapid increase in anti-HBs represented an anamnestic response and was considered to indicate the presence of HBsAg-specific immune memory.
anti-HBs titers may no longer be detectable, and to a vigorous anamnestic response, which prevents acute infection, acute disease, prolonged viremia, and chronic infection. The presence of HBsAg-specific memory after HB vaccination was suggested in a number of studies by epidemiological data showing the absence of disease in a vaccinated population and proven by demonstration of an anamnestic anti-HBsresponse after revaccination.
considering adolescents with proadolescents with prowith protective anti-HBs titers and those who responded to the booster dose, protective anti-HBs responses were et al. reported that persistence of vaccine-induced immune memory among adolescents who had received primary HB of HB vaccine booster doses. The mechanism for continued vaccine-induced protection is thought to be the preservation of immune memory through selective specific B and T lymphocytes. Bauer et al. suggested that individuals who had lost their protective anti-HBs still showed immunologic T cell memory and that these T cells were able to trigger anti-HBs production by B cells activated by revaccination. This data indicated that a high proportion of vaccine recipients retained immune memory and would develop antiof undetectable anti-HBs in adolescents who had years prior. Forty-three percent of subjects with antia booster dose of HB vaccine. These non-responders recipients worldwide failed to produce protective anti-HBs titers after receiving a primary dose of HB vaccine.
The higher proportion of non-responders in this study may have been caused by uncertainty of the primary vaccine administration in the subjects, since no written documentation of vaccinations was obtained. have been confused with other vaccination series. This recall bias may have led to overestimation of the prevalence of primary non-responders. The other cause that may play a role was HBV infection. HB surface virus infection. HB infection could not completely be rule out by history taking only.
Revaccination was recommended for those individuals whose post-booster HB vaccination vaccines at monthly intervals and should be re-tested non-responders. Non-responsiveness status is related to genetic factors, such as human leukocyte antibody response to full-dose HB vaccination. This suboptimal antibody response was not caused by critical event in T cell responsiveness to HBsAg.
To our knowledge, this is the first study to vaccination data was rarely kept by parents through the adolescent period, so parents' memory recall was used as a source of vaccination data. Analyses of vaccination coverage with recall and written vaccination data, have shown that recall may be used to estimate vaccination coverage in a population. Recall and written vaccination data were correlated affected the identification of vaccination status of an individual child. Mothers tended to underestimate the number of doses actually received in older children.
hepatitis B vaccinations in the recall only group. The validity of a parent's recall depended upon the vaccine, and it decreased with increasing age of the child at vaccination and with an increasing number of vaccines that the parent had to remember. Thus, to have more accurate results, written documentation of vaccination is needed to evaluate long-term HB vaccine-induced protective immunity.
of HB immunity in adolescents who had received complete primary HB vaccines during infancy based on parents' recall. We detected protective anti-HBs titers in less than half of our subjects, as well as anamnestic response in one-third of subjects, and a after a booster dose of HB vaccine. Further study is needed to determine accurate HB vaccine-induced protecvaccine-induced protection and non-responder prevalence with a larger sample size and written documentation of infant vaccinations. 
